(CDLX) Cardlytics - Overview
Stock: Bank Advertising, Customer Analytics, Loyalty Marketing, Purchase Data
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 126% |
| Relative Tail Risk | -22.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.19 |
| Alpha | -103.04 |
| Character TTM | |
|---|---|
| Beta | 2.425 |
| Beta Downside | 2.288 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.87% |
| CAGR/Max DD | -0.50 |
Description: CDLX Cardlytics December 22, 2025
Cardlytics, Inc. (NASDAQ: CDLX) runs a native advertising platform that leverages anonymized bank transaction data to deliver targeted, real-time ads across digital channels (web, mobile apps, email, push notifications) in the United States and the United Kingdom. Its two-product suite consists of the Cardlytics platform for brand-level reach and the Bridg customer-data platform, which aggregates point-of-sale and product-level purchase information from merchant partners to enable analytics, loyalty campaigns, and impact measurement. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Key recent metrics (FY 2023): revenue of approximately $86 million, up ~12 % year-over-year, driven largely by a 15 % increase in advertiser spend on its native channel; gross margin stable at ~68 %; and a net loss of $24 million, reflecting continued investment in data-science talent and platform scaling. The broader digital advertising market remains a tailwind, with U.S. ad spend growing ~7 % YoY and a measurable shift toward performance-based, data-rich formats-trends that directly benefit Cardlytics’ value proposition.
Given the company’s reliance on bank-derived data, macro-level factors such as consumer credit-card usage trends, privacy-regulation developments (e.g., GDPR, CCPA), and the health of the retail sector are material drivers of future performance; any contraction in transaction volume or tightening of data-sharing rules could materially impact revenue growth.
For a deeper, data-driven assessment of Cardlytics’ valuation and risk profile, you might find ValueRay’s analytical framework useful.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -110.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 2.39 > 1.0 |
| NWC/Revenue: 6.77% < 20% (prev 9.34%; Δ -2.57% < -1%) |
| CFO/TA -0.00 > 3% & CFO -741.0k > Net Income -110.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.5m) vs 12m ago 6.93% < -2% |
| Gross Margin: 44.37% > 18% (prev 0.43%; Δ 4394 % > 0.5%) |
| Asset Turnover: 72.57% > 50% (prev 73.48%; Δ -0.91% > 0%) |
| Interest Coverage Ratio: -10.05 > 6 (EBITDA TTM -74.0m / Interest Expense TTM 10.0m) |
Altman Z'' -15.00
| A: 0.06 (Total Current Assets 140.7m - Total Current Liabilities 123.7m) / Total Assets 292.8m |
| B: -4.77 (Retained Earnings -1.40b / Total Assets 292.8m) |
| C: -0.29 (EBIT TTM -100.8m / Avg Total Assets 346.1m) |
| D: -4.70 (Book Value of Equity -1.40b / Total Liabilities 297.5m) |
| Altman-Z'' Score: -22.05 = D |
Beneish M -3.58
| DSRI: 0.97 (Receivables 91.4m/109.6m, Revenue 251.2m/293.5m) |
| GMI: 0.98 (GM 44.37% / 43.50%) |
| AQI: 0.96 (AQ_t 0.49 / AQ_t-1 0.52) |
| SGI: 0.86 (Revenue 251.2m / 293.5m) |
| TATA: -0.38 (NI -110.8m - CFO -741.0k) / TA 292.8m) |
| Beneish M-Score: -3.58 (Cap -4..+1) = AAA |
What is the price of CDLX shares?
Over the past week, the price has changed by -6.43%, over one month by -30.82%, over three months by -28.08% and over the past year by -72.46%.
Is CDLX a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CDLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1.6 | 79.1% |
| Analysts Target Price | 1.6 | 79.1% |
| ValueRay Target Price | 0.5 | -44% |
CDLX Fundamental Data Overview February 05, 2026
P/B = 2.1492
Revenue TTM = 251.2m USD
EBIT TTM = -100.8m USD
EBITDA TTM = -74.0m USD
Long Term Debt = 168.6m USD (from longTermDebt, last quarter)
Short Term Debt = 47.7m USD (from shortTermDebt, last quarter)
Debt = 221.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 177.5m USD (from netDebt column, last quarter)
Enterprise Value = 225.2m USD (47.7m + Debt 221.4m - CCE 44.0m)
Interest Coverage Ratio = -10.05 (Ebit TTM -100.8m / Interest Expense TTM 10.0m)
EV/FCF = -23.35x (Enterprise Value 225.2m / FCF TTM -9.64m)
FCF Yield = -4.28% (FCF TTM -9.64m / Enterprise Value 225.2m)
FCF Margin = -3.84% (FCF TTM -9.64m / Revenue TTM 251.2m)
Net Margin = -44.12% (Net Income TTM -110.8m / Revenue TTM 251.2m)
Gross Margin = 44.37% ((Revenue TTM 251.2m - Cost of Revenue TTM 139.7m) / Revenue TTM)
Gross Margin QoQ = 46.70% (prev 46.27%)
Tobins Q-Ratio = 0.77 (Enterprise Value 225.2m / Total Assets 292.8m)
Interest Expense / Debt = 1.32% (Interest Expense 2.92m / Debt 221.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -79.6m (EBIT -100.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.14 (Total Current Assets 140.7m / Total Current Liabilities 123.7m)
Debt / Equity = -47.07 (negative equity) (Debt 221.4m / totalStockholderEquity, last quarter -4.70m)
Debt / EBITDA = -2.40 (negative EBITDA) (Net Debt 177.5m / EBITDA -74.0m)
Debt / FCF = -18.41 (negative FCF - burning cash) (Net Debt 177.5m / FCF TTM -9.64m)
Total Stockholder Equity = 47.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.02% (Net Income -110.8m / Total Assets 292.8m)
RoE = -235.7% (Net Income TTM -110.8m / Total Stockholder Equity 47.0m)
RoCE = -46.75% (EBIT -100.8m / Capital Employed (Equity 47.0m + L.T.Debt 168.6m))
RoIC = -30.49% (negative operating profit) (NOPAT -79.6m / Invested Capital 261.1m)
WACC = 3.49% (E(47.7m)/V(269.1m) * Re(14.85%) + D(221.4m)/V(269.1m) * Rd(1.32%) * (1-Tc(0.21)))
Discount Rate = 14.85% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 16.44%
Fair Price DCF = unknown (Cash Flow -9.64m)
EPS Correlation: 60.99 | EPS CAGR: 25.15% | SUE: 2.45 | # QB: 3
Revenue Correlation: -57.72 | Revenue CAGR: -13.61% | SUE: -0.46 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.31 | Chg30d=-0.003 | Revisions Net=+0 | Growth EPS=+37.6% | Growth Revenue=-5.5%